Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
The collective voice of early phase COVID-19 vaccine trial participants: Insights for improving confidence in novel vaccines.
Thomas TM. et al, (2023), Human vaccines & immunotherapeutics, 19
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Silk SE. et al, (2023), Med, 4, 668 - 686.e7
Systematic review of the diagnosis and management of necrotising otitis externa: Highlighting the need for high-quality research.
Takata J. et al, (2023), Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 48, 381 - 394
UK consensus definitions for necrotising otitis externa: a Delphi study.
Hodgson SH. et al, (2023), BMJ Open, 13
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO. et al, (2023), Science translational medicine, 15
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.
Hodgson SH. et al, (2022), Clinical and translational science, 15, 524 - 534
Characteristics, management and outcome of large Necrotising Otitis Externa case series: Need for Standardised Case Definition.
Hodgson SH. et al, (2022), J Laryngol Otol, 1 - 32
Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.
Kimingi HW. et al, (2022), Frontiers in immunology, 13
Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal Testing
Vanderslott S. et al, (2021), Science, Technology, & Human Values, 016224392110570 - 016224392110570
Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom
Vanderslott S. et al, (2021), BMJ Global Health, 6, e006305 - e006305
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Development of clinical prediction models for outcomes of complicated intra-abdominal infection.
Ahmed S. et al, (2021), The British journal of surgery
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
Hodgson SH. et al, (2021), The Lancet. Infectious diseases, 21, e26 - e35
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478